A Phase 1/2 interventional study of Dexmedetomidine Hydrochloride in Hyperactive Delirium and Delirium of Mixed Origin, sponsored by Bruyère Health Research Institute.. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Bruyère Health Research Institute. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.
Among the 78 studies testing dexmedetomidine in Delirium, this one is the 67th largest by enrollment, is one of 7 that started in 2022, is the only one in phase 1/2, and was the 56th registered.
935 studies on the registry are indexed under Delirium; 188 are open to participants now.
Browse Delirium studies →14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 60+
Tanta University · Sites in Egypt
Ages 21+
Tanta University · Sites in Egypt
Ages 65+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Douglas Fraser · Sites in Canada
Ages 1 mo–17 yrs
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 12 · Phase 4 35
First in 2004; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 111 across 551 interventional studies indexed under Delirium.
Median enrollment 98 across the 78 interventional studies. Of the 37 that completed or were terminated, 8 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 78 have an industry lead sponsor. The 10 most frequent:
Bruyère Health Research Institute. is the lead sponsor of 10 studies on the registry; 6 are open to participants now.
Bruyère Health Research Institute. has 1 study filed under Delirium — fewer than ten, so there is no comparison to draw.
3 of the studies testing dexmedetomidine in Delirium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06192615Phase 3Massachusetts General HospitalMinimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II) | 2027-10-31 |
| NCT04669457University of Massachusetts, WorcesterPediatric Delirium | 2027-04-05 |
| NCT07781462Alexandria UniversityIntravenous Infusion of Low Dose Ketamine Versus Dexmedetomedine for Delirium Treatment in Acute Heart Failure | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies testing dexmedetomidine in Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated delirium among patients near the end of life followed by a palliative care provider in a non-monitored setting. Fifty patients will receive dexmedetomidine (0.4 mcg/kg/hour, titrated up to 1.0 mcg/kg/hour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be measured.
Delirium is a common and challenging complication to manage at the end of life. An estimated 75% (range 58-88%) of patients experience delirium during a palliative inpatient admission in the weeks prior to death. Delirium is classified on the basis of psychomotor activity into hypoactive, hyperactive, and mixed subtypes. Agitation is a feature of both the hyperactive and mixed subtypes and, when present, the episode of delirium is conventionally referred to as agitated delirium. Agitated delirium is characterized by increased agitation, verbal or physical aggression, and perceptual disturbance. Furthermore, these episodes can cause the patient, their families, and the care team significant distress by decreasing a patient's ability to communicate with loved ones and the care team. Studies of patients who recall their delirium experience during an inpatient hospital admission report high levels of distress, and that this distress is exacerbated by being aware of their inability to communicate with family and the healthcare team.
However, studies demonstrate distress associated with delirium is greater among family members compared to that experienced by patients. In the context of palliative care, agitated delirium in the dying phase is particularly devastating for family members - the inability to meaningfully communicate with a loved one during final interactions with them, and to witness the visible distress that characterizes agitated delirium, can cause significant anguish. Several studies demonstrate severe levels of distress among a majority of caregivers who have cared for a loved one with delirium. Family members of patients with terminal delirium report negative physical and psychological burden associated with delirium, including family member feelings of distress, anxiety, and helplessness, exhaustion, and difficulty coping. Additionally, caregiver-perceived delirium in the last 6 months of life has been found to be associated with significantly increased risk - up to 12x - of symptoms of generalized anxiety among family caregivers. In particular, patient symptoms characteristic of agitated delirium, such as restlessness and agitation, psychotic symptoms, cognitive impairment, and communication difficulties, are associated with greater levels of psychological and emotional distress among family members. Bereaved family members express experiencing anger and sadness that they could not have meaningful interactions with their loved one at the end of life, and felt delirium robbed them prematurely of these interactions before death and hindered their opportunity to say goodbye. Family members have further described this phenomenon as distress related to premature loss of the caregiver-patient relationship and the loss of a familiar person becoming a stranger. Family members also report distress related to decision-making that balances their desire for meaningful communication at the end of life with reducing patient suffering. Most commonly, this dilemma is manifested in family member decisions around the use of sedation.
Agitated delirium also has a marked impact on nursing staff and their ability to assess patient needs. Qualitative investigations of palliative care nurses' experiences caring for patients with delirium found nurses had difficulty managing patient delirium in a way they felt maintained patients' dignity and "minimized chaos", and reported delirium and related symptoms were highly distressing for them. Specifically, delirium-related distress experienced by nurses has been shown to be significantly associated with patient delirium severity and the presence and severity of perceptual disturbances. Clinical professionals have also expressed negative effects of delirium on their interactions with family members, with disagreements and tension arising from different understandings of patient needs.
There is limited evidence to support the use of pharmacological interventions for the management of delirium symptoms in palliative care patients, and no medication currently approved in Canada for the indication of delirium. However, published guidelines do recognize a limited role for the use of medications (such as low doses of antipsychotics and/or benzodiazepines) in distressed delirious patients or if there are safety concerns. Among imminently dying patients, pharmacological sedation (e.g., with midazolam, methotrimeprazine, or phenobarbital) is often used to manage agitated delirium; however, use of these medications to manage delirium in the dying phase is based on case series and expert opinion. More broadly, clinical guidelines and systematic reviews of palliative pharmacological sedation conclude that evidence for the efficacy of sedation for symptom control using these medications is insufficient. Additionally, sedation to treat agitated delirium is limited in that it generally eliminates patients' ability to be alert and interact with others, a limitation that, as outlined above, is often contrary to patients' goals of care and the well-being of family members. There is a need for alternative interventions that better align with patients' goals of care and support patients, family members, and clinical staff through meaningful communication at the end of life.
An increasing number of small case series and reviews suggest dexmedetomidine may be an effective and safe option for managing agitated delirium in palliative care. Dexmedetomidine is a centrally active alpha-2 receptor agonist that has mild sedative and opioid co-analgesic effects without suppressing respiratory drive. In most acute care hospital settings, dexmedetomidine is restricted for use in the intensive care unit and by anesthesia for short term sedation. Delirium treatment and prevention has commonly been studied as a secondary endpoint in clinical trials of sedation for critically ill patients, largely demonstrating the effectiveness of dexmedetomidine for delirium management over currently used medications in palliative care, including haloperidol, midazolam, and propofol. Given dexmedetomidine is currently the only agent recommended for treatment of agitated delirium in critically ill patients, pilot data reports have emerged regarding its use in other settings where agitated delirium is highly prevalent, namely palliative care. The largest and most recent case series (n=6) of dexmedetomidine to manage agitated delirium reported improved patient agitation and distress in all cases while maintaining a rousable, conscious state, providing patients the opportunity to interact with others at the end of life. Similarly, additional case studies of agitated delirium in palliative care (total n=4) have all reported successful resolution and/or symptom control of patients' agitated delirium at the end of life. In terms of dosage, these therapeutic benefits were predominantly achieved with moderate to high doses of dexmedetomidine (e.g., 0.5 mcg/kg/hr-1.5 mcg/kg/hr). Similarly, initial findings from our unpublished retrospective case series of dexmedetomidine to manage agitated delirium in palliative care (n=10) revealed moderate success at dose levels of 0.4 mcg/kg/hr-0.7 mcg/kg/hr, but minimal success at low dose levels of 0.2 mcg/kg/hr-0.3 mcg/kg/hr.
In contrast to other medications commonly used to manage agitated delirium, dexmedetomidine provides rousable sedation, better supporting communication needs and goals of care at the end of life. Dexmedetomidine is now off-patent, reducing previous cost barriers to use. In addition, while dexmedetomidine is administered intravenously in critical care, advance preparation for subcutaneous administration is more conducive to use in palliative care. To facilitate this, our team recently completed stability testing and demonstrated >90% retention of dexmedetomidine 20mcg/ml in 0.9% sodium chloride in polyvinylchloride bags after 9 days of storage at both room temperature (25°C ± 2°C) and refrigeration (4°C ± 2°C ) (accepted for publication). Furthermore, evidence demonstrates subcutaneous administration of dexmedetomidine results in a relative bioavailability of about 80%.
The investigators propose to evaluate the safety, feasibility, and preliminary efficacy of dexmedetomidine for the management of agitated delirium in palliative care. There are currently no approved therapies for agitated delirium in palliative care, but evidence from critical care, reduced medication costs, and published case series in palliative care suggest dexmedetomidine may be effective to treat this challenging condition. A therapy that might treat delirium without causing excess sedation, allowing patients to continue interactions with their loved ones and care team, would be a "game changer" in palliative care. There is the potential to improve end-of-life care for patients and their families in a manner that is more consistent with their goals of care and provides necessary symptom management while reducing the distress experienced by family and healthcare team members.
Details of Eligibility, Intervention Protocol, and Outcome Measures are provided elsewhere.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meeting one of the following criteria:
Exclusion Criteria:
Participants will be given a starting low dose of 0.4 mcg/kg/hr, to be titrated up to a medium dose of 0.7 mcg/kg/hr and potentially up to a maximum dose of 1.0 mcg/kg/hr by subcutaneous infusion until the target RASS-PAL level has been achieved.
Drug: Dexmedetomidine Hydrochloride
Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
Also known as: Dexmedetomidine, Precedex
Dosing - Therapeutic Dose
Dose at which the target Richmond Agitation Sedation Scale-Palliative (RASS-PAL) score of -1 ("drowsy"), 0 ("alert and calm"), or +1 ("restless") is achieved. The RASS-PAL is a 10-point scale with scores ranging from -5 (not rousable) to +4 (combative).
Time frame: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Dosing - Time
Time (in hours) at which the target Richmond Agitation Sedation Scale-Palliative (RASS-PAL) score of -1 ("drowsy"), 0 ("alert and calm"), or +1 ("restless") is achieved. The RASS-PAL is a 10-point scale with scores ranging from -5 (not rousable) to +4 (combative).
Time frame: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Number of Participants With Adverse Events - Bradycardia
Proportion of participants with Bradycardia (two consecutive readings of heart rate (HR)\<40 beats/minute)
Time frame: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Number of Participants With Adverse Events - Hypotension
Proportion of participants with Hypotension (systolic blood pressure(SBP) \< 70 mmHg or 40% drop from baseline with lightheadedness or loss of consciousness.
Time frame: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Number of Participants With Adverse Events - Skin Tolerability
Proportion of participants with skin intolerability of the infusion site, based on the National Cancer Institute Common Toxicity for Adverse Events.
Time frame: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Recruitment Rate
Number of patients enrolled divided by number of patients approached.
Time frame: Through study completion, up to 1 year
Cost
Comparison of total drug cost of dexmedetomidine (accounting for total dosage administered and duration of therapy) and compare the total cost to that of the alternative first line sedative identified by the treating physician.
Time frame: Through study completion, up to 13 months
Baseline Agitation
Measured using the Richmond Agitation Sedation Scale-Palliative (RASS-PAL). The RASS-PAL is a 10-point scale with scores ranging from -5 (not rousable) to +4 (combative).
Time frame: Baseline
Baseline Delirium Severity
Measured using the Nursing Delirium Screening Tool (Nu-DESC). Nu-DESC scores range from 0 to 10, with higher scores indicating worse delirium.
Time frame: Baseline
Change in Agitation
Measured using the Richmond Agitation Sedation Scale-Palliative (RASS-PAL). RASS-PAL is a 10-point scale with scores ranging from -5 (not rousable) to +4 (combative).
Time frame: Measured at Day 1 - 1 hour post administration, one hour post any dose change, and once daily from Day 1 to intervention completion (up to 13 months)
Change in Delirium Severity
Measured using the Nursing Delirium Screening Tool (Nu-DESC). Nu-DESC scores range from 0 to 10, with higher scores indicating worse delirium.
Time frame: Measured every 8 hours from Day 1 to intervention completion (up to 13 months)
Baseline Pain
Measured using the Critical Care Pain Observation Tool (CPOT) (higher score indicates worse pain).
Time frame: Baseline
Change in Pain From Baseline
Measured using the Critical Care Pain Observation Tool (CPOT) (higher score indicates worse pain).
Time frame: Measured once daily from Day 1 to intervention completion (up to 13 months)
Baseline Opioid Use
Measured using the oral Morphine-Equivalent Daily Dose (MEDD) and frequency of breakthrough dose for each participant
Time frame: Measured at Baseline
Change in Opioid Use From Baseline
Measured using the oral Morphine-Equivalent Daily Dose (MEDD) and frequency of breakthrough dose for each participant
Time frame: Measured once daily from Day 1 to intervention completion (up to 13 months)
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Jan 2025, 28 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Jan 2024 → Sep 2022, primary completion Jan 2026 → Jan 2025 and completion Mar 2026 → Jan 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Bruyère Health Research Institute.